Cerus Corporation is adjusting its previously stated product revenue guidance range. The Company expects full-year 2023 product revenue to be in the range of $155 million to $158 million. The revision is due in part to the delay in signing the now executed IFC sales agreement with one of the largest U.S. producers of cryoprecipitate.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.76 USD | +0.57% |
|
+4.14% | -18.52% |
05-02 | Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.52% | 325M | |
+13.62% | 130B | |
-9.08% | 10.81B | |
-18.14% | 7.12B | |
+48.89% | 5.96B | |
-34.21% | 3.98B | |
+8.03% | 3.43B | |
-19.31% | 2.48B | |
-18.50% | 1.91B | |
-24.94% | 1.66B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023